Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer

被引:964
作者
Macheda, ML [1 ]
Rogers, S [1 ]
Best, JD [1 ]
机构
[1] Univ Melbourne, St Vincents Hosp, Dept Med, Fitzroy, Vic 3065, Australia
关键词
D O I
10.1002/jcp.20166
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Malignant cells are known to have accelerated metabolism, high glucose requirements, and increased glucose uptake. Transport of glucose across the plasma membrane of mammalian cells is the first rate-limiting step for glucose metabolism and is mediated by facilitative glucose transporter (GLUT) proteins. Increased glucose transport in malignant cells has been associated with increased and deregulated expression of glucose transporter proteins, with overexpression of GLUT1 and/or GLUT3 a characteristic feature. Oncogenic transformation of cultured mammalian cells causes a rapid increase of glucose transport and GLUT] expression via interaction with GLUT1 promoter enhancer elements. In human studies, high levels of GLUT] expression in tumors have been associated with poor survival. Studies indicate that glucose transport in breast cancer is not fully explained by GLUT] or GLUT3 expression, suggesting involvement of another glucose transporter. Recently, a novel glucose transporter protein, GLUT1 2, has been found in breast and prostate cancers. In human breast and prostate tumors and Cultured cells, GLUT] 2 is located intracellularly and at the cell surface. Trafficking of GLUT] 2 to the plasma membrane could therefore contribute to glucose uptake. Several factors have been implicated in the regulation of glucose transporter expression in breast cancer. Hypoxia can increase GLUT1 levels and glucose uptake. Estradiol and epidermal growth factor, both of which can play a role in breast cancer cell growth, increase glucose consumption. Estradiol and epidermal growth factor also increase GLUT1 2 protein levels in cultured breast cancer cells. Targeting GLUT1 2 could provide novel methods for detection and treatment of breast and prostate cancer. J. Cell. Physiol. (C) 2004 Wiley-Liss, Inc.
引用
收藏
页码:654 / 662
页数:9
相关论文
共 121 条
[1]  
Alò PL, 2001, AM J CLIN PATHOL, V116, P129
[2]   Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095 [J].
Arakawa, K ;
Ishihara, T ;
Oku, A ;
Nawano, M ;
Ueta, K ;
Kitamura, K ;
Matsumoto, M ;
Saito, A .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (02) :578-586
[3]  
ASANO T, 1991, J BIOL CHEM, V266, P24632
[4]  
Avril N, 2001, J NUCL MED, V42, P9
[5]   Expression of the human erythrocyte glucose transporter Glut1 in cutaneous neoplasia [J].
Baer, SC ;
Casaubon, L ;
Younes, M .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (04) :575-577
[6]   Deregulation of hexose transporter expression in Caco-2 cells by ras and polyoma middle T oncogenes [J].
BaronDelage, S ;
Mahraoui, L ;
Cadoret, A ;
Veissiere, D ;
Taillemite, JL ;
Chastre, E ;
Gespach, C ;
Zweibaum, A ;
Capeau, J ;
BrotLaroche, E ;
Cherqui, G .
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY, 1996, 270 (02) :G314-G323
[7]   POSITRON EMISSION TOMOGRAPHY IN THE STUDY OF HUMAN-TUMORS [J].
BEANEY, RP .
SEMINARS IN NUCLEAR MEDICINE, 1984, 14 (04) :324-341
[8]   MOLECULAR-BIOLOGY OF MAMMALIAN GLUCOSE TRANSPORTERS [J].
BELL, GI ;
KAYANO, T ;
BUSE, JB ;
BURANT, CF ;
TAKEDA, J ;
LIN, D ;
FUKUMOTO, H ;
SEINO, S .
DIABETES CARE, 1990, 13 (03) :198-208
[9]  
Binder C, 1997, ANTICANCER RES, V17, P4299
[10]   TRANSFORMATION OF RAT FIBROBLASTS BY FSV RAPIDLY INCREASES GLUCOSE TRANSPORTER GENE-TRANSCRIPTION [J].
BIRNBAUM, MJ ;
HASPEL, HC ;
ROSEN, OM .
SCIENCE, 1987, 235 (4795) :1495-1498